PL2297115T3 - Pochodne di-alkoksychinazolin jako inhibitory receptora KDR - Google Patents

Pochodne di-alkoksychinazolin jako inhibitory receptora KDR

Info

Publication number
PL2297115T3
PL2297115T3 PL09743783T PL09743783T PL2297115T3 PL 2297115 T3 PL2297115 T3 PL 2297115T3 PL 09743783 T PL09743783 T PL 09743783T PL 09743783 T PL09743783 T PL 09743783T PL 2297115 T3 PL2297115 T3 PL 2297115T3
Authority
PL
Poland
Prior art keywords
dialkoxyquinazoline
derivatives
kdr inhibitors
kdr
inhibitors
Prior art date
Application number
PL09743783T
Other languages
English (en)
Inventor
Wei-Guo Su
Weihan Zhang
Xiaoqiang Yan
Yumin Cui
Yongxin Ren
Jifeng Duan
Original Assignee
Hutchison Medipharma Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Entpr Ltd filed Critical Hutchison Medipharma Entpr Ltd
Publication of PL2297115T3 publication Critical patent/PL2297115T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL09743783T 2008-05-09 2009-05-08 Pochodne di-alkoksychinazolin jako inhibitory receptora KDR PL2297115T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/118,019 US7829574B2 (en) 2008-05-09 2008-05-09 Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
PCT/US2009/043347 WO2009137797A2 (en) 2008-05-09 2009-05-08 Quinazoline derivatives
EP09743783.4A EP2297115B1 (en) 2008-05-09 2009-05-08 Dialkoxyquinazoline derivatives as kdr inhibitors

Publications (1)

Publication Number Publication Date
PL2297115T3 true PL2297115T3 (pl) 2015-12-31

Family

ID=41265455

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09743783T PL2297115T3 (pl) 2008-05-09 2009-05-08 Pochodne di-alkoksychinazolin jako inhibitory receptora KDR

Country Status (22)

Country Link
US (3) US7829574B2 (pl)
EP (1) EP2297115B1 (pl)
JP (2) JP5856842B2 (pl)
KR (2) KR101686679B1 (pl)
AU (1) AU2009244130B2 (pl)
BR (1) BRPI0908675B1 (pl)
CA (1) CA2723148C (pl)
CY (1) CY1117222T1 (pl)
DK (1) DK2297115T3 (pl)
ES (1) ES2550245T3 (pl)
HR (1) HRP20150954T1 (pl)
HU (1) HUE025723T2 (pl)
MX (2) MX2010012168A (pl)
MY (1) MY155566A (pl)
NZ (1) NZ588900A (pl)
PH (1) PH12013500363A1 (pl)
PL (1) PL2297115T3 (pl)
PT (1) PT2297115E (pl)
RU (1) RU2506261C2 (pl)
SI (1) SI2297115T1 (pl)
TW (1) TWI458724B (pl)
WO (1) WO2009137797A2 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
BRPI1008325A2 (pt) * 2009-02-11 2020-08-25 Merck Patent Gmbh carboxamidas azaeterocíclicas de amino
ES2900504T3 (es) 2009-09-03 2022-03-17 Bristol Myers Squibb Co Quinazolinas como inhibidores de los canales iónicos de potasio
CN105461702A (zh) 2014-09-10 2016-04-06 和记黄埔医药（上海）有限公司 6-(6,7-二甲氧基喹唑啉-4-基氧基)-n,2-二甲基苯并呋喃-3-甲酰胺晶型
US20190112317A1 (en) 2015-10-05 2019-04-18 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
US11016085B2 (en) 2016-04-25 2021-05-25 The Johns Hopkins University ZNT8 assays for drug development and pharmaceutical compositions
EP3652540A4 (en) 2017-07-12 2021-04-07 The Johns Hopkins University PROTEOLIPOSOME BASED ZNT-8 SELF-ANTIGENT FOR THE DIAGNOSIS OF TYPE 1 DIABETES
US11236077B2 (en) 2018-03-30 2022-02-01 Hangzhou Solipharma Co., Ltd. Fruquintinib eutectic crystal, preparation method therefor, composition, and uses thereof
WO2020037174A1 (en) 2018-08-16 2020-02-20 The Johns Hopkins University Antibodies to human znt8
CN111184698A (zh) * 2018-11-15 2020-05-22 和记黄埔医药（上海）有限公司 呋喹替尼制剂及其应用
US12366570B2 (en) 2019-10-01 2025-07-22 The Johns Hopkins University Cell-based ZNT8 assay
CN110898065A (zh) * 2019-11-25 2020-03-24 南通大学 呋喹替尼或其盐在制备治疗脉络膜新生血管药物中的用途
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
US6235741B1 (en) 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
BRPI0017548B8 (pt) * 1999-02-10 2023-05-02 Astrazeneca Ab Composto
US6943161B2 (en) 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
DE10009267A1 (de) 2000-02-26 2001-08-30 Goedecke Ag Verfahren zur einfachen Herstellung von (3-Chlor-4-fluor-phenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazolin-4-yl]-amin bzw. (3-Chlor-4-fluor-phenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazolin-4-yl]-amin
AR035851A1 (es) * 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
AU2001292138A1 (en) * 2000-10-13 2002-04-22 Astrazeneca Ab Quinazoline derivatives with anti-tumour activity
AU2001292137A1 (en) * 2000-10-13 2002-04-22 Astrazeneca Ab Quinazoline derivatives
US20040092750A1 (en) 2001-03-01 2004-05-13 Tomoyuki Hasegawa 2-methylindole-4-acetic acid, process for producing the same, and process for producing intermediate therefor
WO2003048159A1 (en) * 2001-12-05 2003-06-12 Astrazeneca Ab Quinoline derivatives
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
BR0313059B8 (pt) 2002-07-29 2021-07-27 Rigel Pharmaceuticals composto, e, composição farmacêutica
WO2005005395A2 (en) * 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag Arylamine-substituted quinazolinone compounds
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
GB0318423D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
JP4503022B2 (ja) 2003-12-23 2010-07-14 ファイザー・インク 新規キノリン誘導体
WO2005097134A2 (en) * 2004-03-31 2005-10-20 The Scripps Research Institute Quinazoline based protein kinase inhibitors
US20070299092A1 (en) 2004-05-20 2007-12-27 Wyeth Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors
WO2005114219A2 (en) * 2004-05-20 2005-12-01 Wyeth Assays to identify irreversibly binding inhibitors of receptor tyrosine kinases
WO2006071079A1 (en) 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
US20060281712A1 (en) 2005-06-14 2006-12-14 Chi-Feng Yen Pyrimidine compounds
JP2009518382A (ja) 2005-12-05 2009-05-07 ファイザー・プロダクツ・インク Ｖｅｇｆ−ｒ阻害剤を調製する方法
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
GB0604937D0 (en) * 2006-03-10 2006-04-19 Novartis Ag Organic compounds
WO2007133773A2 (en) 2006-05-15 2007-11-22 Senex Biotechnology, Inc Identification of cdki pathway inhibitors
TW200922590A (en) * 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases

Also Published As

Publication number Publication date
PH12013500363A1 (en) 2013-09-02
RU2506261C2 (ru) 2014-02-10
RU2010150345A (ru) 2012-06-20
BRPI0908675A2 (pt) 2015-08-04
WO2009137797A2 (en) 2009-11-12
US20090281130A1 (en) 2009-11-12
MX2010012168A (es) 2011-02-18
US7829574B2 (en) 2010-11-09
HRP20150954T1 (hr) 2015-10-09
MX2014001023A (es) 2014-05-22
US8212033B2 (en) 2012-07-03
WO2009137797A3 (en) 2010-02-25
US20120238572A1 (en) 2012-09-20
EP2297115A2 (en) 2011-03-23
EP2297115B1 (en) 2015-07-22
BRPI0908675B1 (pt) 2022-01-25
KR20160045925A (ko) 2016-04-27
MY155566A (en) 2015-10-30
TWI458724B (zh) 2014-11-01
HUE025723T2 (en) 2016-04-28
JP2014177499A (ja) 2014-09-25
CY1117222T1 (el) 2017-04-05
JP2011519956A (ja) 2011-07-14
US8497372B2 (en) 2013-07-30
US20110015213A1 (en) 2011-01-20
SI2297115T1 (sl) 2015-10-30
KR101686679B1 (ko) 2016-12-14
MX340021B (es) 2016-06-22
NZ588900A (en) 2012-12-21
TW201002694A (en) 2010-01-16
JP5856842B2 (ja) 2016-02-10
AU2009244130B2 (en) 2012-11-01
AU2009244130A1 (en) 2009-11-12
ES2550245T3 (es) 2015-11-05
CA2723148A1 (en) 2009-11-12
EP2297115A4 (en) 2012-03-14
DK2297115T3 (en) 2015-08-10
CA2723148C (en) 2015-01-20
KR20110013381A (ko) 2011-02-09
PT2297115E (pt) 2015-10-26

Similar Documents

Publication Publication Date Title
TWI365185B (en) Amidophenoxyindazoles useful as inhibitors of c-met
IL207099A0 (en) 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of-??-secretase (bace)
PT2297115E (pt) Derivados de quinazolina
IL210548A0 (en) Spiroaminodihydrothiazine derivatives
ZA201102423B (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
ZA201100799B (en) Imidazopyridin-2-one derivatives
SG10201506608RA (en) 3-deazaneplanocin derivatives
ZA201006719B (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
IL210406A0 (en) Pyrrolopyridinylpyrimidin - 2 - ylamine derivatives
ZA201102449B (en) Morpholinopurine derivatives
IL208336A0 (en) Pyrisazinone derivatives
IL210869A0 (en) Imidazothiadiazoles derivatives
EP2381777A4 (en) AZAINDOL DERIVATIVES AS KINASEHEMMER
IL211290A0 (en) New 2-amidothiadiazole derivatives
ZA201100948B (en) Acylaminobenzamide derivatives
ZA201005382B (en) Substituted heteroarylamide diazepinopyrimidone derivatives
PL2297162T3 (pl) Związki
IL213424A0 (en) Quinazolinamide derivatives
IL210164A0 (en) Thiazolylpiperidine derivatives
ZA201007431B (en) Imidazolidinone derivatives as 11b-hsd1 inhibitors
ZA201005381B (en) Substituted heteroarylamide oxazepinopyrimidone derivatives
ZA201008052B (en) 2-phenyl-4-cyclopropyl-pyrimidine derivatives
IL213051A0 (en) Difluorophenyldiacylhydrazide derivatives
GB0821710D0 (en) Derivatives of dihydroindolone
GB0821711D0 (en) Dihydroindolone derivatives